Medicorp

1001 Sam Peny Boulevard Fredericksburg, VA 22401 (540) 741-1100

NMSBI

05 May 2006

U.S. Nuclear Regulatory Commission Region I 475 Allendale Road King of Prussia, Pennsylvania

19406-1415

03008082

RE: NRC Material License 45-00935-02

Dear Sir or Madam:

Please amend the above referenced license to authorize David G. Landsnes, MD for 35.300 in addition to 35.100 and 35.200. Enclosed is documentation that Dr. Landsnes was an authorized user in the past for this category under New York State Department of Health Radioactive Materials License No. 530. If you have any questions or if I may be of further assistance, please contact me at your convenience.

Sincerely,

Linda Prowett, BLS, CNMT, NCT

Linda Troust

Radiation Safety Officer

540-741-1580

Paul Prewitt

Vice President,

Ambulatory Services and Properties

138821

NMSS/RGNI MATERIALC-602

REC'D IN LAT MAY 1 0 2006

PHONE NO. : 540 361 2902 WITH MED KEHAR



STATE OF NEW YORK DEPARTMENT OF HEALTH

Flanigan Square, 547 River Street, Troy, New York 12180

Antonia C. Novello, M.D., M.P.H. Commissioner

Dennis P. Whalen Executive Deputy Commissioner

AUG 2 9 2000

United Health Services, Inc. Wilson Memorial Regional Medical Center 33-57 Harrison Street Johnson City, New York 13790

Attention: David Lisi, M.D.

Radiation Safety Officer

RE:

NYS Dept. of Health Radioactive

Materials License No. 530

DH No. 00-303

Dear Dr. Lisi:

Enclosed is New York State Department of Health Radioactive Materials License No. 530, which marnes Dr. David G. Lamines as an authorized user of radiopharmaceuticals for diagnostic purposes and Iodine 131 for radiopharmaceutical therapy.

If I may be of assistance, please contact this office at 518/402-7590 or:

New York State Department of Health Bureau of Environmental Radiation Protection Radioactive Materials Section Flanigan Square - Room 530 547 River Street Troy, New York 12180-2216

Sincerely,

Robert E. Dansereau

Associate Radiological Health Specialist

SG/RD

Enclosure:

Amendment No. 77

cc: Marthew J. Salanger, President and CEO

License Number

530

Amendment Number

77

DH Numbers

00-303

United Health Services, Inc. Wilson Memorial Regional Medical Center 33-57 Harrison Street Johnson City, New York 13790

Attention:

David Lisi, M.D.

Radiation Safety Officer

Dear Licensee:

In accordance with the request dated July 17, 2000, signed by Matthew J. Salanger, Marvin Guter, M.D., and David Lisi, M.D., New York State Department of Health Radioactive Materials License No. 530 is amended as follows:

Change Condition No. 10 to Read:

10. A. Radioactive material listed in Item 6 shall be used by, or under the tutelage of the following individuals, with the specified limitations:

S. Rao Aravapalli, M.D.

Subitems A. B. D. E. G. J. and K.

Jesse Aronowitz, M.D.

Subitems L and M

Lawrence Cadkin, M.D.

Subitems A through K

Renaldo Fernandez, M.D.

Subitems A through K

Andrew W. Guldschmidt, M.D.

Subitems A. B. D. E. G. J. and K.

Thomas F. Gudas, M.D.

Subitems A, B, D, E, G, J, and K

Marvin Guter, M.D.

Subitems A through K

Seung Shin Hahn, M.D.

Subitems L and M

David G. Landsnes, M.D.

Subitems A. B, D, E, F, G, J and K

David N. Lisi, M.D.

Subitems A. B. D. E. G. J. and K

License Number

530

Amendment Number

75

DH Numbers

00-97

00-98

United Health Services, Inc. Wilson Memorial Regional Medical Center 33-57 Harrison Street Johnson City, New York 13790

Attention:

David Lisi, M.D.

Radiation Safety Officer

Dear Licensee:

In accordance with the requests dated March 1, 2000, signed by Matthew J. Salanger and David Lisi, M.D., New York State Department of Health Radioactive Materials License No. 530 is amended as follows:

Change Condition No. 6 to Read:
Radioactive Materials 7. 0

6. Radioactive Materials (element & mass no.)

Chemical and/or
Physical Form

8. Maximum quantity licensee may possess at one time

A. Any radioactive material A. as described in 10 NYCRR

as described in 10 NYCRR 16.123(b)(1), except alpha or positron emitting isotopes Any radiopharmaceutical as described in 10 NYCRR 16.123(b)(1)

A. As necessary for uses in Subitem 9A

B. Any radioactive material B.

as described in 10 NYCRR 16.123(b)(2), except alpha or positron emitting isotopes Any radiopharmaceutical, generator, or reagent kit as described in 10 NYCRR 16.123(b)(2)

B. As necessary for uses in Subitem 9B

CONDITIONS

License No. 530 Amendment No. 75 C. Any radioactive material C. As necessary for uses Anv in Subitem 9C as described in radiopharmaceutical 10 NYCRR as described in 16.123(b)(3), except 10 NYCRR alpha or positron 16.123(b)(3). lodine 131 emitting isotopes restricted to capsule form only Đ. Fluorine 18 D. Fluorodeoxyglucose D. 3 unit doses E. Xenon 133 E. Gas or saline solution E. 200 millicuries F. F. Iodine 131 Sodium iodide F. As necessary for uses in Subitem 9E G. Gadolinium 153 G. Sealed source (DuPont G. 300 millicuries per Pharmaceuticals Model source, not to exceed Number NES8412) 1 curie total Η. Carbon 14 H. Any Η. 5 millicuries 1. lodine 125 1. Any 1. 5 millicuries Cesium 137 100 millicuries J. J. Sealed source (Isotope J. Products Laboratories (maximum of 30 Model HEG-137) millicuries per source) K. Depleted Uranium K. Metal alloy K. 120 pounds L. 500 millicuries Palladium 103 L. Sealed sources 500 millicuries M. lodine 125 M. Sealed sources M.

Change Condition No. 9 to Read:

- 9. Authorized use (unless otherwise described, the authorized place of use is the licensee's address stated in Item 2, above).
 - A. Any diagnostic procedure involving measurement of uptake, dilution, or excretion, as described in 10 NYCRR 16.123 (b) (1).

CONDITIONS

License No. 530 Amendment No. 75

- 9. B. Any diagnostic procedure involving imaging and localization studies, as described in 10 NYCRR 16.123 (b) (2).
 - C. Any therapeutic procedure described in 10 NYCRR 16.123 (b) (3).
 - D. Any diagnostic procedure involving imaging and localization studies as described in 10 NYCRR 16.123 (b) (2).
 - E. Evaluation of pulmonary function, blood pool, and/or cerebral blood flow studies.
 - F. For treatment of hyperthyroidism, cardiac dysfunction, and/or thyroid carcinoma.
 - G. For use in an ADAC Advantage Non-Uniform Attenuation Correction System.
 - H. and I. In vitro procedures only.
 - J. Two sources for use in an ADAC MCD-AC System for attenuation correction, and two others for source exchange as detailed in operating procedures submitted to the Department.
 - K. For use as shielding in an ADAC MCD-AC System.
 - L. and M. For interstitial brachytherapy.

Change Condition No. 10 to Read:

10. A. Radioactive material listed in Item 6 shall be used by, or under the tutelage of the following individuals, with the specified limitations:

S. Rao Aravapalli, M.D.

Subitems A, B, D, E, G, J, and K

William F. Arndt III, M.D.

Subitems A, B, D, E, G, J, and K

Jesse Aronowitz, M.D.

Subitems L and M

Lawrence Cadkin, M.D.

Subitems A through K

CONDITIONS

License No. 530 Amendment No. 75

Renaldo Fernandez, M.D. Subitems A through K Andrew M. Goldschmidt, M.D. Subitems A, B, D, E, G, J, and K Thomas F. Gudas, M.D. Subitems A, B, D, E, G, J, and K Marvin Guter, M.D. Subitems A through K 10. A. (Continued) Silviu Landman, M.D. Subitems A, B, D, E, G, J, and K Seung Shin Hahn, M.D. Subitems L and M David N. Lisi, M.D. Subitems A, B, D, E, G, J, and K Vincent Montone, M.D. Subitems A, B, D, E, G, J, and K George Petro, M.D. Subitems A, B, D, E, G, J, and K Larry Poe, M.D. Subitems A, B, D, E, G, J, and K Anwer H. Puthawala, M.D. Subitems A, B, D, E, F, G, J, and K Thomas M. Ralston, M.D. Subitems A, B, D, E, F, G, J, and K Jay Riccardi, M.D. Subitems A, B, D, E, G, J, and K Edward D. Santelli, M.D. Subitems A, B, D, E, G, J, and K John J. Siess, M.D. Subitems A, B, D, E, G, J, and K Michael R. Stone, M.D. Subitems A, B, D, E, F, G, J, and K Russell J. Tarner, M.D. Subitems A, B, D, E, F, G, J, and K Quirino V. Wong, M.D. Subitems A through K

B. Radioactive material listed in Item 6 shall be used by David Lisi, M.D., as appropriate to fulfill the responsibilities of the Radiation Safety Officer.

CONDITIONS

License No. 530 Amendment No. 75

Change Condition No. 11 to Read:

- 11. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license, in accordance with statements, representations, and procedures contained in the documents (including any enclosures) listed below:
 - A. LLRW minimization plan dated July 9, 1992, signed by Mark T. O'Neil, Jr.
 - B. Application for New York State Department of Health Radioactive Materials License dated August 31, 1992, signed by Mark T. O'Neil, Jr.
- 11. C. Letter dated May 16, 1995, signed by Quirino Wong, M.D.
 - D. Letter dated April 27, 1998, signed by Quirino Wong, M.D. and Matthew J. Salanger.
 - E. Letter dated December 15, 1998, signed by Matthew J. Salanger and Quirino Wong, M.D.
 - F. Letter dated March 1, 2000, signed by Matthew J. Salanger and David Lisi, M.D.
 - G. Letter dated April 3, 2000, signed by Matthew J. Salanger and David Lisi, M.D.

The New York State Department of Health's regulations shall govern the licensee's statements in applications or letters unless the statements are more restrictive than the regulations.

Add Condition No. 27 to Read:

27. The licensee shall not acquire licensed material in a sealed source or device that contains a sealed source unless the source or device has been registered with the US Nuclear Regulatory Commission, the New York State Department of Health, the New York State Department of Labor, the New York City Department of Health, or with any Agreement State.

			75 dos
vviille	Lee	- 530_	_75.doc
a manyage comme	may it has affected a	CONTRACTOR OF THE CO	CONTRACTOR INTERNAL

D	ac	_	6
	a_{y}	P	v

CONDITIONS

License No. 530 Amendment No. 75

FOR THE NEW YORK STATE DEPARTMENT OF HEALTH

Date:

By_

SG/CAC

Stephen M. Gavitt, Chief Radioactive Materials Section Bureau of Environmental Radiation

Protection

cc: Matthew J. Salanger, President and CEO